Delivering extraordinary. Empowering ordinary.
We’re developing novel oral medicines for rare diseases to help patients take part in the everyday activities they enjoy.
Learn MoreStructure-guided Drug Design
We combine traditional cell biology with medicinal chemistry to build synthetic compounds that bind to specific protein targets to fight disease.
See Our ScienceBuilding a Rare Disease Drug Portfolio
We are developing a pipeline of oral drugs for rare diseases, including our next generation kallikrein inhibitor for hereditary angioedema (HAE).
View Our PipelineRecent News
Stay up to date with the latest discoveries, events, and reports from BioCryst.
-
BioCryst Appoints Rare Disease Expert Theresa Heggie to Board of Directors
-
BioCryst Presents Data Highlighting the Rapid and Sustained Plasma Concentrations of BCX7353 in HAE Patients at the Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology
-
BioCryst to Present at Upcoming Investor Conferences
Join Our Team
We are a collection of passionate individuals united by a commitment to scientific excellence and an unwavering focus on the needs of patients.
JOB OPENINGS